{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancers+-+Stomach", "query": { "condition": "Gastrointestinal Cancers - Stomach" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 935, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancers+-+Stomach&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T16:08:14.781Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MSI-H/dMMR Gastroesophageal-junction Cancer", "MSI-H/dMMR Gastric Cancer" ], "interventions": [ { "name": "S095029", "type": "DRUG" }, { "name": "pembrolizumab 200 mg (KEYTRUDA ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-08-31", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 3, "location_summary": "Ocala, Florida • Noblesville, Indiana • Houston, Texas", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116136" }, { "nct_id": "NCT00165464", "title": "Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "GE Junction Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2001-08", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-04-28", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00165464" }, { "nct_id": "NCT03102229", "title": "Real-time Activity Monitoring to Prevent Admissions During RadioTherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer of the Head and Neck", "Cancer of Lung", "Cancer of Esophagus", "Cancer of Stomach" ], "interventions": [ { "name": "Enhanced Supportive Care - Status Checks", "type": "OTHER" }, { "name": "Enhanced Supportive Care - Referrals", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2016-07", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03102229" }, { "nct_id": "NCT00120939", "title": "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Ovarian Neoplasms", "Prostatic Neoplasms", "Lung Neoplasms", "Gastrointestinal Neoplasms" ], "interventions": [ { "name": "Motexafin Gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-04-03", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120939" }, { "nct_id": "NCT03597581", "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Gastric Cancer", "Gastric Neoplasm", "KRAS Mutation-Related Tumors", "CRC", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "ompenaclid", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2018-06-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 17, "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597581" }, { "nct_id": "NCT01747551", "title": "FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ziv-aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-01", "completion_date": "2017-07-26", "has_results": true, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747551" }, { "nct_id": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Remzistotug", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "GSK5764227", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2022-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 7, "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277051" }, { "nct_id": "NCT02366819", "title": "Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "Stage IIB Gastric Cancer", "Stage IIIA Esophageal Adenocarcinoma", "Stage IIIA Gastric Cancer", "Stage IIIB Esophageal Adenocarcinoma", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Adenocarcinoma", "Stage IIIC Gastric Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2014-12-11", "completion_date": "2026-06-08", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 3, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02366819" }, { "nct_id": "NCT03890731", "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "BAY73-4506 (Regorafenib, Stivarga)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-02", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03890731" }, { "nct_id": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rovalpituzumab Tesirine", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2016-12-14", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-06-25T16:08:14.781Z", "location_count": 5, "location_summary": "La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000257" } ] }